Legal and Ethical Values in the Resolution of Research-Related Disputes: How Can IRBs Respond to Participant Complaints?

Abstract

Under US federal regulations, participants providing informed consent must receive information regarding whom to contact in case of a research-related injury or complaint. Although informed consent processes routinely direct participants to contact institutional review boards (IRBs) with questions or concerns, there has been little empirical study of the ways in which IRBs act to resolve participants' research-related complaints. This article explores available literature on participant complaints, considers the responsibilities of IRBs in dispute resolution, and outlines a research agenda. As a case study, this review considers disputes arising from HIV/AIDS research, focusing on novel issues arising from biomedical HIV prevention trials.

Keywords

dispute resolution participant complaint institutional review board research-related injury

Get full access to this article

View all access options for this article.

References

21 C.F.R. § 50.25(a)(7). (2012).

45 C.F.R. § 46.111(a)(2). (2012).

45 C.F.R. § 46.116(a)(6). (2012).

45 C.F.R. § 46.116(a)(7). (2012).

Abbott

, & Grady

(2010). A systematic review of the empirical literature evaluating IRBs: What we know and what we still need to learn. Journal of Empirical Research on Human Research Ethics, 6(1), 3–19.

Agency for Healthcare Research and Quality. (2009). Sample forms: Sample combined informed consent and authorization forms. Retrieved from www.ahrq.gov/funding/grants/policies/informedconsent/icform3c.html.

Alvarez

R. A.

Vasquez

Mayorga

C. C.

Feaster

D. J.

, & Mitrani

V. B.

(2006). Increasing minority research participation through community organization outreach. Western Journal of Nursing Research, 28(5), 541–560; discussion 561–543.

Association for the Accreditation of Human Research Protection Programs Inc. (2009). AAHRPP Accreditation Standards. Washington, DC: AAHRPP.

Association for the Accreditation of Human Research Protection Programs Inc. (2011). 2011 Metrics on Human Research Protection Program Performance (21 pp.). Washington, DC: AAHRPP.

10.

Association for the Accreditation of Human Research Protection Programs Inc. (2013). Evaluation Instrument for Accreditation (131 pp). Washington, DC: AAHRPP.

11.

Ayala

Durazo

, & Apel

(2006). When human participants in research complain, ask questions or express concern: Protecting vulnerable populations in an HMO setting. Paper presented at the American Public Health Association Meeting, Boston, MA.

12.

Burris

, & Cameron

(2008). The case against criminalization of HIV transmission. JAMA, 300(5), 578–581.

13.

Chua

Ford

Wilson

, & Cawthorne

(2005). The tenofovir pre-exposure prophylaxis trial in Thailand: Researchers should show more openness in their engagement with the community. PLoS Medicine, 2(10), e346.

14.

Corbie-Smith

Thomas

S. B.

Williams

M. V.

, & Moody-Ayers

(1999). Attitudes and beliefs of African Americans toward participation in medical research. Journal of General Internal Medicine, 14(9), 537–546.

15.

Cox

L. E.

, & Kerkering

T. M.

(1993). Grievance procedures as assurance for the HIV-infected clinical trial participant. AIDS Patient Care Journal, 7(1), 20–21.

16.

DeVille

(2002). The role of litigation in human research accountability. Accountability in Research, 9, 17–43.

17.

DeVille

K. A.

(2007). The jury is out: Pre-dispute binding arbitration agreements for medical malpractice claims. Journal of Legal Medicine, 28, 333–395.

18.

Dhalla

, & Poole

(2011). Barriers of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. Vaccine, 29(35), 5850–5859.

19.

Earnshaw

V. A.

, & Chaudoir

S. R.

(2009). From conceptualizing to measuring HIV stigma: A review of HIV stigma mechanism measures. AIDS & Behavior, 13(6), 1160–1177.

20.

Editorial. (2004). The trials of tenofovir trials. Lancet, 365, 1111.

21.

Elliott

(2012). Justice for injured research subjects. New England Journal of Medicine, 367(1), 6–8.

22.

Essack

Koen

Barsdorf

Slack

Quayle

Milford

(2010). Stakeholder perspectives on ethical challenges in HIV vaccine trials in South Africa. Developing World Bioethics, 10(1), 11–21.

23.

Excler

J.-L.

Kochhar

Kapoor

Das

Bahri

Ghosh

M. D.

(2008). Preparedness for AIDS vaccine trials in India. Indian Journal of Medical Research, 127, 531–538.

24.

Fisher

C. B.

(1999). Relational ethics and research with vulnerable populations. Reports on research involving persons with mental disorders that may affect decision-making capacity. Commissioned papers by the National Bioethics Advisory Commission (pp. 29–49). Rockville, MD: National Bioethics Advisory Commission.

25.

Fisher

C. B.

(2002). Participant consultation: Ethical insights into parental permission and confidentiality procedures for policy relevant research with youth. In Lerner

R. M.

Jacobs

, & Wertlieb

(Eds.), Handbook of Applied Developmental Science (Vol. 4, pp. 371–396). Thousand Oaks, CA: Sage.

26.

Fisher

C. B.

(2011). Addiction research ethics and the Belmont principles: Do drug users have a different moral voice? Substance Use & Misuse, 46(6), 728–741.

27.

Fisher

C. B.

Oransky

Mahadevan

Singer

Mirhej

, & Hodge

(2008). Marginalized populations and drug addiction research: Realism, mistrust, and misconception. IRB, 30(3), 1–9.

28.

Fisher

C. B.

, & Wallace

S. A.

(2000). Through the community looking glass: Reevaluating the ethical and policy implications of research on adolescent risk and psychopathology. Ethics & Behavior, 10(2), 99–118.

29.

Flory

, & Emanuel

(2004). Interventions to improve research participants' understanding in informed consent for research: A systematic review. Journal of the American Medical Association, 292(13), 1593–1601.

30.

Gibbs

J. N.

(2004). State regulation of pharmaceutical clinical trials. Food & Drug Law Journal, 59, 265.

31.

Global Campaign for Microbicides. (2009). Preventing prevention trial failures: A case study and lessons for future trials from the 2004 tenofovir trial in Cambodia. Washington, DC: Global Campaign for Microbicides at PATH.

32.

Gordon

M. P.

(2009). A legal duty to disclose individual research findings to research subjects? Food & Drug Law Journal, 64, 225–260.

33.

Grant

R. M.

Buchbinder

Cates

Willard J.

Clarke

Coates

Cohen

M. S.

(2005). Promote HIV chemoprophylaxis research, don't prevent it. Science, 309, 2170–2171.

34.

Guillemin

Gillam

Rosenthal

, & Bolitho

(2012). Human research ethics committees: Examining their roles and practices. Journal of Empirical Research on Human Research Ethics, 7(3), 38–49.

35.

Haire

B. G.

(2011). Because we can: Classes of perspectives over researcher obligation in the failed PrEP trials. Developing World Bioethics, 11, 63.

36.

Harrington

(2009). Community involvement in HIV and tuberculosis research. Journal of Acquired Immune Deficiency Syndromes, 52(Supp), S63–S66.

37.

Harris

G. E.

(2006). Practicing HIV/AIDS community-based research. AIDS Care, 18(7), 731–738.

38.

Hollander-Blumoff

(2010). Just negotiation. Washington University Law Review, 88, 381.

39.

Hollander-Blumoff

, & Tyler

T. R.

(2011). Procedural justice and the rule of law: Fostering legitimacy in alternative dispute resolution. Journal of Dispute Resolution, 2011, 1–19.

40.

Jansson

R. L.

(2003). Researcher liability for negligence in human subjects research: Informed consent and researcher malpractice actions. Washington Law Review, 78, 229–263.

41.

Jay

J. S.

, & Gostin

L. O.

(2012). Ethical challenges of preexposure prophylaxis for HIV. JAMA, 308(9), 867–868.

42.

Kass

N. E.

Natowicz

M. R.

Hull

S. C.

Faden

R. R.

Plantinga

Gostin

L. O.

, & Slutsman

(2003). The use of medical records in research: What do patients want? Journal of Law, Medicine & Ethics, 31, 429–433.

43.

Klitzman

(2011). Views and experiences of IRBs concerning research integrity. Journal of Law, Medicine & Ethics, 39, 513.

44.

Ladimer

(1988). Protection of human subjects: Remedies for injury. In Spicker

S. F.

Alon

de Vries

, & Engelhardt

H. T.

Jr. (Eds.), The use of human beings in research (pp. 261–274). Norwell, MA: Kluwer Academic Publishers.

45.

Logie

James

Tharao

, & Loutfy

M. R.

(2012). Opportunities, ethical challenges, and lessons learned from working with peer research assistants in a multi-method HIV community-based research study in Ontario, Canada. Journal of Empirical Research on Human Research Ethics, 7(4), 10–19.

46.

Macklin

(2011). Ethical challenges in HIV microbicide research: What protections do women need? International Journal of Feminist Approaches to Bioethics, 4(2), 124–143.

47.

Macklin

(2012). Ethics in HIV prevention research: Clarifying the complexities. American Journal of Bioethics, 22(6), 31–32.

48.

Mamotte

Wassenaar

, & Singh

(2013). Compensation for research-related injury in NIH-sponsored HIV/AIDS clinical trials in Africa. Journal of Empirical Research on Human Research Ethics, 8(1), 45–54.

49.

Mantell

J. E.

Morar

N. S.

Myer

, & Ramjee

(2006). “We have our protector”: Misperceptions of protection against HIV among participants in a microbicide efficacy trial. American Journal of Public Health, 96, 1073–1077.

50.

McGrory

Irvin

, & Heise

(2009). Research Rashomon: Lessons from the Cameroon pre-exposure prophylaxis trial site. Washington DC: Global Campaign for Microbicides at PATH.

51.

Mello

Studdert

D. M.

, & Brennan

T. A.

(2003). The rise of litigation in human subjects research. Annals of Internal Medicine, 139, 40–46.

52.

Mills

E. J.

Singh

J. A.

Orbinski

J. J.

Warren

, & Upshur

R. E.

(2005). Designing research in vulnerable populations: Lessons from HIV prevention trials that stopped early. British Medical Journal, 331(7529), 1403–1406.

53.

Millum

(2011). Post-trial access to antiretrovirals: Who owes what to whom? Bioethics, 25, 145.

54.

Mishkin

B. F.

, & Dolan

M. V.

(2006). The role of institutional review boards in managing risk to research institutions and their human research subjects. In Gosfield

A. G.

(Ed.), Health law handbook (pp. 7: 2–28). Eagan, MN: Westlaw.

55.

Morreim

E. H.

(2003). Medical research litigation and malpractice tort doctrines: Courts on a learning curve. Houston Journal of Health Law & Policy, 4, 1–86.

56.

Morreim

E. H.

(2004). Litigation in clinical research: Malpractice doctrines versus research realities. Journal of Law, Medicine & Ethics, 32, 474–481.

57.

Morreim

E. H.

(2005). Clinical trials litigation: Practical realities as seen from the trenches. Accountability in Research, 22, 47.

58.

Moss

(2007). If institutional review boards were declared unconstitutional, they would have to be reinvented. Northwestern University Law Review, 202, 801.

59.

Motil

K. J.

Allen

, & Taylor

(2004). When a research subject calls with the complaint, what will the institutional review board do? IRB: Ethics & Human Research, 26, 9.

60.

Newman

P. A.

Logie

James

Charles

Maxwell

Salam

, & Woodford

(2011). “Speaking the dialect”: Understanding public discourse in the aftermath of an HIV vaccine trial shutdown. American Journal of Public Health, 101(9), 1749–1758.

61.

NIH Department of Bioethics. (2013). Clinical and research ethics services. Retrieved from www.bioethics.nih.gov/clinical/.

62.

Office for Human Research Protections. (1993a). Tips on informed consent. Retrieved from www.hhs.gov/ohrp/policy/ictips.html.

63.

Office of Human Research Protections. (1993b). Chapter III: Basic IRB review institutional review board guidebook. Retrieved from www.hhs.gov/ohrp/archive/irb/irb_chapter3.htm#e6.

64.

Oransky

Fisher

C. B.

Mahadevan

, & Singer

(2009). Barriers and opportunities for recruitment for non-intervention studies on HIV risk: Perspectives of street drug users. Substance Use & Misuse, 44(11), 1642–1659.

65.

Paasch-Orlow

M. K.

, & Brancati

F. L.

(2005). Assessment of medical school institutional review board policies regarding compensation of subjects for research-related injury. American Journal of Medicine, 118(2), 175–180.

66.

Padian

N. S.

Buvé

Balkus

Serwadda

, & Cates

(2008). Biomedical interventions to prevent HIV infection: Evidence, challenges, and way forward. Lancet, 372, 585–599.

67.

Pike

E. R.

(2012). Recovering from research: A no-fault proposal to compensate injured research participants. American Journal of Law & Medicine, 38, 7.

68.

Poteat

Diouf

Drame

F. M.

Ndaw

Traore

Dhaliwal

(2011). HIV risk among MSM in Senegal: A qualitative rapid assessment of the impact of enforcing laws that criminalize same sex practices. PLoS One, 6(12), e28760.

69.

Prentice

E. D.

Epperson

K. J.

Kratochvil

C. J.

, & Gordon

B. G.

(2002). IRB review of adverse events. In Amdur

& Bankert

(Eds.), Institutional review board management and function (pp. 297–300). Sudbury, MA: Jones and Bartlett.

70.

Rekart

M. L.

(2006). Sex-work harm reduction. Lancet, 366(9503), 2123–2134.

71.

Resnik

D. B.

(2006). Compensation for research-related injuries: Ethical and legal issues. Journal of Legal Medicine, 27, 263.

72.

Rhodes

S. D.

Malow

R. M.

, & Jolly

(2010). Community-based participatory research: A new and not-so-new approach to HIV/AIDS prevention, care, and treatment. AIDS Education & Prevention, 22(3), 173–183.

73.

Rose

B. S.

, & Lodato

(2006). Emerging litigation involving human research subjects: A future for class actions? The Brief, 35(4), 1–12.

74.

Ross

L. F.

Loup

Nelson

R. M.

Botkin

J. R.

Kost

Smith

G. R.

, & Gehlert

(2010). The challenges of collaboration for academic and community partners in a research partnership: Points to consider. Journal of Empirical Research on Human Research Ethics, 5(1), 19–31.

75.

Rotheram-Borus

M. J.

Swendeman

, & Chovnick

(2009). The past, present, and future of HIV prevention: Integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annual Review of Clinical Psychology, 5, 143–167.

76.

Sahay

, & Mehendale

(2011). Engaging community to support HIV prevention research. Eastern Journal of Medicine, 16, 168–177.

77.

Saver

R. S.

(2006). Medical research and intangible harm. University of Cincinnati Law Review, 74, 941.

78.

Saver

R. S.

(2009). At the end of the clinical trial: Does access to investigational technology end as well? Western New England Law Review, 31, 411.

79.

Scott

L. D.

(2003). Research-related injury: Problems and solutions. Journal of Law, Medicine & Ethics, 31, 419.

80.

Shagi

Vallely

Kasindi

Chiduo

Desmond

Soteli

(2008). A model for community representation and participation in HIV prevention trials among women who engage in transactional sex in Africa. AIDS Care, 20(9), 1039–1049.

81.

Singh

J. A.

, & Mills

E. J.

(2005). The abandoned trials of pre-exposure prophylaxis for HIV: What went wrong? PLoS Medicine, 2(9), e234.

82.

Smith

, & Martinez

(2009). An analytic framework for dispute systems design. Harvard Negotiation Law Review, 14, 123–169.

83.

Stoddard

D. G.

(2010). Falling short of fundamental fairness: Why institutional review board regulations fail to provide procedural due process. Creighton Law Review, 43, 1275.

84.

Szmania

S. J.

Johnson

A. M.

, & Mulligan

(2008). Alternative dispute resolution in medical malpractice: A survey of emerging trends and practices. Conflict Resolution Quarterly, 26(1), 71–96.

85.

The Lewin Group. (2005). Task Order No. 2: Care/Compensation for injuries in clinical research. Draft of the final report prepared for the Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation. Falls Church, VA: Lewin Group.

86.

UNAIDS/WHO. (2012). UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS.

87.

U.S. Department of Health and Human Services. (1979). The Belmont Report. Washington, DC: Department of Health, Education, and Welfare.

88.

U.S. General Accounting Office. (1999). Medical records privacy: Access needed for health research, but oversight of privacy protection is limited (32 pp.). Washington, DC: GAO.

89.

Walker

, & Hamilton

R. T.

(2011). Employee-employer grievances: A review. International Journal of Management Reviews, 13, 40–58.

90.

Weijer

, & LeBlanc

G. J.

(2006). The balm of Gilead: Is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation? Journal of Law, Medicine & Ethics, 34(4), 793–808.

91.

White

Chileshe

Dawson

Donnell

Hillier

Morar

(2011). Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa. Clinical Trials, 8(1), 103–111.

92.

Wolfe

, & Cohen

(2010). Human rights and HIV prevention, treatment, and care for people who inject drugs: Key principles and research needs. Journal of Acquired Immune Deficiency Syndromes, 55(Suppl 1), S56–S62.

93.

World Health Organization. (2013). Informed consent for clinical studies [template]. Retrieved from www.who.int/entity/rpc/research_ethics/InformedConsent-clinicalstudies.doc.